HOME >> BIOLOGY >> NEWS
HAART therapy significantly prolongs survival in AIDS patients with central nervous system lymphoma

DALLAS July 30, 2003 AIDS patients with primary central nervous system lymphoma who receive the HAART "cocktail" therapy live much longer than those not treated with the therapy, researchers at UT Southwestern Medical Center at Dallas found.

A study published in today's issue of the journal AIDS reports that patients treated with HAART Highly Active Antiretroviral Therapy survived at least 22 months, compared with a median of 29 days for those who didn't take the prescription drug regimen.

"Traditionally, patients with primary central nervous system lymphoma have a very poor prognosis with a survival of only a few weeks to months after diagnosis," said Dr. Daniel Skiest, associate professor of internal medicine at UT Southwestern and the study's senior author.

Skiest, also the associate chief for clinical infectious diseases at UT Southwestern, reviewed records of AIDS patients diagnosed with central nervous system lymphoma at Parkland Memorial Hospital a 990-bed hospital serving Dallas County which is the primary teaching institution of Southwestern Medical School between 1995 and 2001 to determine the effects of HAART on survival rates.

During the six-year study, 25 patients were identified. Of those, 19 were definite cases of CNS lymphoma and six were probable cases. Six of seven patients treated with HAART survived at least one year and 10 months after diagnosis. The 18 who did not receive the therapy all died.

Of those who died, patients who received radiation therapy lived longer. Eleven patients who received neither HAART nor radiation had a median survival of only 29 days.

"While HAART has led to much better outcomes in many AIDS-related complications, it has not been clear whether there is a benefit of HAART in patients with primary CNS lymphoma," Skiest said. "Ours is only the second series to demonstrate a significant survival benefit. It is not yet clear whether the survival benefit is related to prev
'"/>

Contact: Rachel Horton
rachel.horton@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center
30-Jul-2003


Page: 1 2

Related biology news :

1. Treatment With IL-2 Plus HAART Markedly Reduces HIV In Immune System "Hiding Places"
2. The Perils Of Discontinuing Therapy: Without HAART, Cytokines Stimulate HIV From Latently Infected Cells
3. Targeted therapy knocks out pediatric brain cancer in mice
4. New anti-inflammatory strategy for cancer therapy identified by UCSD researchers
5. Columbia research to examine gene influence on severity of peridontal disease, therapy response
6. Case for IBD combination therapy comes from research at Baylor, MIT and Hebrew University
7. The search for a kinder, gentler chemotherapy
8. Embryonic stem cell therapy shows steady benefits in rebuilding infarcted heart
9. Retroviral gene therapy? ASLV, HIV, and MLV show distinct target site preferences
10. Gene changes linked to increased eye pressure may have implications for glaucoma therapy
11. Jefferson Lab detector technology aids development of cystic fibrosis therapy

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/2/2020)... ... July 01, 2020 , ... AltruBio Inc. http://www.altrubio.com , ... biologic for the treatment of steroid-refractory acute graft-versus-host disease (SR-aGVHD), at European Hematology ... Martin of the Fred Hutchinson Cancer Research Center, this single-arm, open-label Phase 1 ...
(Date:6/28/2020)... ... , ... In an upcoming episode scheduled for the fall of 2020, Advancements ... (POCT). Check local listings for more info. , Today, the majority of testing is ... labs throughout the country. Results are then available several days later. Now, in an ...
(Date:6/23/2020)... ... June 23, 2020 , ... ... pleased to announce the next event in a series of TOPIQ webinars, which ... TOPIQ series of webinars was developed in response to social distancing measures that ...
Breaking Biology News(10 mins):
(Date:8/15/2020)... Ore. (PRWEB) , ... August 13, 2020 , ... ... the creation of its Scientific Advisory Board (SAB) to research the medical potential ... cannabis can be enhanced when combined with terpenes. The board is focused on expanding ...
(Date:8/12/2020)... ... August 11, 2020 , ... The FSHD ... Facioscapulohumeral Muscular Dystrophy Clinical Trial Research Network (FSHD CTRN), with consideration ... is a consortium of academic research centers in the United States and Europe ...
(Date:8/12/2020)... ... August 12, 2020 , ... Inc. magazine today revealed ... in FDA compliance consulting has been named on its annual Inc. 5000 list, ... a unique look at the most successful companies within the American economy’s most ...
(Date:8/3/2020)... ... August 03, 2020 , ... ... Jim Corrigan, President and CEO has been named one of the 100 most ... industry sectors, PharmaVoice 100 honorees are selected based on how they have inspired ...
Breaking Biology Technology:
Cached News: